HHLR Advisors, Ltd. 13D and 13G filings for Kiniksa Pharmaceuticals, Ltd.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:39 pm Purchase |
2023-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
HHLR Advisors, Ltd. | 3,879,426 9.900% |
338,125 (+9.55%) |
Filing |
| 2023-08-18 4:32 pm Purchase |
2022-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
HHLR Advisors, Ltd. | 3,541,301 9.900% |
917,377 (+34.96%) |
Filing |
| 2023-02-14 4:08 pm Sale |
2022-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
HHLR Advisors, Ltd. | 2,623,924 7.600% |
-296,099 (-10.14%) |
Filing |
| 2021-02-16 4:24 pm Purchase |
2020-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
HHLR Advisors, Ltd. | 2,920,023 9.200% |
1,024,135 (+54.02%) |
Filing |